Atossa Therapeutics posts Q3 2025 results update

Atossa Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025 and providing a company update.

Rhea-AI Filing Summary

Atossa Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025 and providing a company update. The press release, dated November 12, 2025, is included as Exhibit 99.1 and incorporated by reference into this report. The company clarifies that the information in Items 2.02 and 9.01, including Exhibit 99.1, is being furnished rather than filed under securities law, which limits its use for certain liability provisions.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Atossa Therapeutics (ATOS) report in this Form 8-K?

Atossa Therapeutics reported that it issued a press release announcing its financial results for the quarter ended September 30, 2025 and provided a company update, which is furnished as Exhibit 99.1.

Which period do the Atossa Therapeutics (ATOS) results in this update cover?

The update covers Atossa Therapeutics’ financial results for the quarter ended September 30, 2025.

How are the Atossa Therapeutics (ATOS) Q3 2025 results provided to investors?

The Q3 2025 results and company update are provided through a press release dated November 12, 2025, attached to the report as Exhibit 99.1.

Are the Atossa Therapeutics (ATOS) Q3 2025 results considered 'filed' with the SEC?

The company states that the information in Items 2.02 and 9.01, including Exhibit 99.1, is furnished and not deemed to be filed for purposes of certain liability provisions under the federal securities laws.

What exhibits are included with this Atossa Therapeutics (ATOS) Form 8-K?

The report includes Exhibit 99.1, a press release dated November 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed this Atossa Therapeutics (ATOS) Form 8-K?

The report was signed on behalf of Atossa Therapeutics, Inc. by Mark J. Daniel, Chief Financial Officer and principal financial and accounting officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 08:40 AM EST Learn about SEC filing dates

false000148803900014880392025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35610	26-4753208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
10202 5th Avenue NE, Suite 200
Seattle, Washington				98125
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.18 par value		ATOS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated November 12, 2025
104		Cover page Interactive Data File (embedded within the Inline XBRL document)

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Atossa Therapeutics, Inc.
Date:	November 12, 2025	By:	/s/ Mark J. Daniel
			Mark J. Daniel Chief Financial Officer (Principal Financial and Accounting Officer)